Patent ID: 6673771
Filing Date: 2004-01-06
Classification: A61K,A61P,C07K

Abstract:
A method for treating bone loss in a patient, which method comprises the step of administering to said patient an amount of an inhibitor of TNF-related activator induced cytokine (TRANCE)/Receptor activator of NF-B ligand (RANK) that is effective to inhibit osteoclastogenesis or osteoclast function, wherein the inhibitor is a specific peptide having the formula:R1â€”R2â€”R3â€”R4â€”R5 wherein:R1 is 1-5 amino acid residues; R2 is a linking amino acid residue; R3 is selected from the group consisting of DRGWA (SEQ ID NO:1); DGDLAT (SEQ ID NO:2); SDFATE (SEQ ID NO:3); VKTSIKIPSSH (SEQ ID NO:4); TKTSIKIPSSH (SEQ ID NO:5); KTSIKIPSSH (SEQ ID NO:6); YWSNSEF (SEQ ID NO:7); YWNSE (SEQ ID NO:8); PDQDAP (SEQ ID NO:9); PDSWH (SEQ ID NO:10); SKEL (SEQ ID NO:11); EIEF (SEQ ID NO:12); SRSGHS (SEQ ID NO:13); RFQEEIKENTKNDKQ (SEQ ID NO:14); TSYPD (SEQ ID NO:15); KENTK (SEQ ID NO:16); and SEQ ID NOS:1-16 with one or more amino acid residues substituted with another residue in the same designated class; R4 is a linking amino acid residue; R5 is 1-5 amino acid residues; and wherein R2 and R4 are bound to each other, thereby forming a cyclic portion which includes R2, R3 and R4 with R1 and R5 forming exocyclic portions, and one or both of R1 and R5 comprising at least one tyrosine or phenylalanine.